Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Neurocrine: 4Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
02/04/2020 | 04:56pm EDT

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported fourth-quarter profit of $34 million.

On a per-share basis, the San Diego-based company said it had profit of 35 cents.

The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 82 cents per share.

The biopharmaceutical company posted revenue of $244.1 million in the period, exceeding Street forecasts. Four analysts surveyed by Zacks expected $242.4 million.

For the year, the company reported profit of $37 million, or 39 cents per share. Revenue was reported as $788.1 million.

Neurocrine shares have dropped 4% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $103.10, a climb of 17% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NEUROCRINE BIOSCIENCES, IN
04/06NEUROCRINE BIOSCIENCES : Provides COVID-19 Business Update
AQ
04/06VOYAGER THERAPEUTICS : Provides Update on the RESTORE-1 Parkinson's Disease Tria..
AQ
04/03NEUROCRINE BIOSCIENCES : Provides COVID-19 Business Update
PR
02/25NEUROCRINE BIOSCIENCES : to Present at Cowen 40th Annual Health Care Conference
PR
02/07NEUROCRINE BIOSCIENCES : Management's Discussion and Analysis of Financial Condi..
AQ
02/05NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Fina..
AQ
02/04NEUROCRINE : 4Q Earnings Snapshot
AQ
02/04NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Chan..
AQ
02/04NEUROCRINE BIOSCIENCES : Reports Fourth Quarter and Full-Year 2019 Financial Res..
PR
02/03NEUROCRINE BIOSCIENCES : Announces Appointment of Shalini Sharp to Board of Dire..
PR
More news
Financials (USD)
Sales 2019 776 M
EBIT 2019 105 M
Net income 2019 78,4 M
Finance 2019 505 M
Yield 2019 -
P/E ratio 2019 111x
P/E ratio 2020 29,5x
EV / Sales2019 10,6x
EV / Sales2020 7,11x
Capitalization 8 704 M
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 119,86  $
Last Close Price 91,22  $
Spread / Highest target 61,1%
Spread / Average Target 31,4%
Spread / Lowest Target 14,0%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.-15.14%7 988
GILEAD SCIENCES19.62%94 124
VERTEX PHARMACEUTICALS16.60%61 693
REGENERON PHARMACEUTICALS34.30%53 154
WUXI APPTEC CO., LTD.-0.12%21 017
BIONTECH SE55.64%13 733